Results 81 to 90 of about 3,351 (178)

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

Blood Advances
: Some patients with chronic lymphocytic leukemia who develop progressive disease (PD) during covalent Bruton tyrosine kinase (BTK) inhibitor treatment acquire resistance mutations in BTK or PLCG2.
Jennifer R. Brown, Jessica Li, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O’Brien, Constantine S. Tam, Lugui Qiu, Ruiqi Huang, Yang Shi, Adam Idoine, Tommi Salmi, Aileen Cleary Cohen, Mazyar Shadman   +12 more
doaj   +1 more source

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny [PDF]

Bruton tyrosine kinase (Btk) has long been known to play a key role in chronic lymphatic leukaemia, Waldenström macroglobulinaemia and other B-cell proliferative disorders.
Camilli, Massimiliano, Menna, Pierantonio   +1 more
core   +1 more source

Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities

Arthritis &Rheumatology, Volume 77, Issue 12, Page 1626-1634, December 2025.
Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley   +1 more source

Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind? [PDF]

Anti-cancer tyrosine kinase inhibitors are less selective than usually believed and may cause cardiovascular off-target effects. Ibrutinib, a firstin-class covalent inhibitor of Bruton tyrosine kinase, is a pillar of treatment of chronic lymphocytic ...
Camilli, Massimiliano, Menna, Pierantonio   +1 more
core   +1 more source

A matching‐adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR‐2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor

British Journal of Haematology, Volume 208, Issue 1, Page 312-316, January 2026.
Georg Heß, Toby A. Eyre, Min‐Hua Jen, Jiewen Zhang, Benjamin Goebel, Sarang Abhyankar, Martin Dreyling   +6 more
wiley   +1 more source

Establishment and Validation of a UPLC-MS/MS Method for Quantitative Determination of Zanubrutinib and Posaconazole in Rat Plasma: Application in Drug–Drug Interaction Studies

Drug Design, Development and Therapy
Hailun Xia,1 Yuxin Shen,1,2 Xinhao Xu,1,2 Jun Wu,1,2 Guanyang Lin,1,2 Xiaoxiang Du1 1Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2School of Pharmaceutical Sciences ...
Xia H, Shen Y, Xu X, Wu J, Lin G, Du X
doaj  

Acyclovir‐unresponsive disseminated herpes zoster in B‐cell chronic lymphocytic leukemia

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 1, Page 87-90, January 2026.
Tabael L. Turan, Thomas K. Eigentler, Ulrike Blume‐Peytavi, Kamran Ghoreschi   +3 more
wiley   +1 more source

Aciclovir‐resistenter Zoster disseminatus bei chronischer lymphatischer B‐Zell‐Leukämie

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 1, Page 87-90, January 2026.
Tabael L. Turan, Thomas K. Eigentler, Ulrike Blume‐Peytavi, Kamran Ghoreschi   +3 more
wiley   +1 more source

Current and future therapies for follicular lymphoma [PDF]

Follicular lymphoma (FL) is an indolent, germinal center B cell–derived lymphoid neoplasm, for which recent advances in treatment have substantially improved patient survival.
Muñoz, Javier, Trotman, Judith, Zinzani, Pier Luigi   +2 more
core   +1 more source

Zanubrutinib and Pterostilbene Intervention in Acute Lymphoblastic Leukemia: An Action Mechanism Unveiled by Network Pharmacology and Machine Learning [PDF]

BIO Web of Conferences
Zanubrutinib, a BTK inhibitor, and pterostilbene, a natural anticancer compound, show potential in combination therapy for Acute Lymphoblastic Leukemia (ALL). Analyzing over 12,000 genes associated with ALL, key hub proteins like LYN, BTK, MYD88, and SYK
Balan G Sakthi, Murugan S Arul, Prabhu Puniethaa, Kalpana B.   +3 more
doaj   +1 more source